Posts

UC Davis C-STEM trains Redlands teachers on bringing co...

Twenty-five teachers from Redlands Unified School District in southern Californi...

Startups to unveil cutting-edge point-of-care technolog...

June 2, 2023 Credit: JODIE ANDRUSKEVICH PHOTO June 2, 2023   Contact: Emily Gowd...

New working group of the GRC is tasked with facilitatin...

Producing the knowledge needed to achieve the Sustainable Development Goals (SDG...

ASCO: Targeted therapy induces responses in HER2-amplif...

ABSTRACT: 4008 Credit: MD Anderson Cancer Center ABSTRACT: 4008 CHICAGO ― HER2-t...

For advanced, HER2-amplified bile duct cancers, antibod...

Bile duct cancers are uncommon and aggressive types of gastrointestinal cancer. ...

Aridis receives FDA agreement on single Phase 3 study f...

Aridis Pharmaceuticals, Inc. received encouraging FDA feedback on their planned ...

Eli Lilly and Novo Nordisk Compete in the Obesity Drug ...

Eli Lilly and Novo Nordisk, two major players in the pharmaceutical industry, ar...

Sanofi’s frexalimab shows early potential in in Phase I...

The anti-CD 40L antibody was associated with a a significant reduction in lesion...

AstraZeneca and MSD’s Lynparza combo bags FDA approval ...

The approval is for the use of Lynparza in combination with Zytiga and prednison...

Pneumagen raises £8 million for further study of intran...

The Scottish company raised further funding to fuel an upcoming Phase IIb study ...

InDex Pharmaceuticals signs licence deal with Viatris f...

InDex will provide funding for the Phase III CONCLUDE programme, an Induction St...

Algernon announces acceptance of Repirinast patent appl...

Repirinast was previously marketed under the brand name Romet in Japan to treat ...

Negative FDA AdCom vote for Intercept’s obeticholic aci...

Additionally, panellists expressed doubts regarding Intercept’s use of a surroga...

UK’s NICE recommends Pfizer’s rimegepant to treat migraine

Up to 145,000 people in England will have the option to choose this treatment.

USPTO grants Notice of Allowance for Tenax Therapeutics...

The patent for oral levosimendan is based on findings obtained from the HELP Study.

New UK intracellular drug delivery centre to support RN...

The new centre will provide access to the infrastructure required to accelerate ...